GlycoMimetics Poster Shows GMI-1271 Reverses Drug Resistance in Multiple Myeloma Models
"The data on GMI-1271 show a promising pathway toward reducing
resistance to chemotherapy and other drugs in multiple myeloma," said
The data in the poster describes a preclinical model mimicking a very high-risk patient population with multiple myeloma. This high-risk group is defined by expression of higher levels of the E-selectin ligand HECA-452 on multiple myeloma cells. HECA-452 expression is also shown to increase in patients as disease progresses. In the animal model reported in the poster, bortezomib did not demonstrate any benefit in the treatment of myeloma with high expression of HECA-452. When GMI-1271 was combined with bortezomib, however, this resistance to bortezomib was overcome, and animals showed improvements in survival compared to bortezomib alone. Resistance to bortezomib is seen in the clinic with shorter and shorter duration of remission as patients' disease progresses. Improving the response to bortezomib could improve clinical outcomes for high risk and relapsed patients with myeloma.
GMI-1271 targets E-selectin, a cell adhesion molecule that aids in blood cancer cell resistance to chemotherapy. The drug candidate also is in a Phase 1/2 clinical study designed to evaluate its safety, pharmacokinetics (PK) and efficacy when used together with chemotherapy in patients with acute myeloid leukemia (AML).
The abstract (Abstract #1805), entitled "E-selectin Ligand Expression Increases with Progression of Myeloma and Induces Drug Resistance in a Murine Transplant Model, which is Overcome by the Glycomimetic E-Selectin Antagonist, GMI-1271," is available at ASH's website.
About
GlycoMimetics's wholly-owned drug candidate (GMI-1271) for AML and other
blood disorders is also in clinical trials.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements regarding the
clinical development of the GMI-1271 and the presentation of data.
Actual results may differ materially from those in these forward-looking
statements. For a further description of the risks associated with these
statements, as well as other risks facing
View source version on businesswire.com: http://www.businesswire.com/news/home/20151205005039/en/
Investor:
sannes@annesassociates.com
or
Media:
jamielacey@presscommpr.com
Source:
News Provided by Acquire Media